



(12) Translation of
European patent specification

(11) NO/EP 2694049 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/137 (2006.01)
A61P 25/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.02.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.10.31
(86)	European Application Nr.	12718064.4
(86)	European Filing Date	2012.04.03
(87)	The European Application's Publication Date	2014.02.12
(30)	Priority	2011.04.05, EP, 11002811 2011.04.29, EP, 11003508
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Tyskland
(72)	Inventor	SCHIENE, Klaus, Schaan 51, 41363 Jüchen, Tyskland STEIGERWALD, Ilona, Lintertstrasse 52, 52078 Aachen, Tyskland HAMON, Michel, NeuropsychopharmacologyFaculty of Medicine Pitié-Salpêtrière91 Boulevard de l'Hôpital, F-75634 Paris Cedex 13, Frankrike SCHNEIDER, Johannes, Rolandstr. 40, 52223 Stolberg, Tyskland REINARTZ, Silvia, Am Kleebach 33, 52080 Aachen, Tyskland JAHNEL, Ulrich, Am alten Flugplatz 68, 42855 Remscheid, Tyskland TZSCHENTKE, Thomas, Königsberger Strasse 78, 52078 Aachen, Tyskland
(74)	Agent or Attorney	Orsnes Patent ApS, Forskerparken 10, 5230 ODENSE, Danmark

(54)	Title	TAPENTADOL FOR PREVENTING CHRONIFICATION OF PAIN
(56)	References Cited:	RAUSCHKOLB-LOEFFLER C ET AL: "Efficacy and tolerability of tapentadol for relief of moderate-to-severe chronic pain due to osteoarthritis of the knee", ANNALS OF THE RHEUMATIC DISEASES, vol. 66, no. Suppl. 2, 16 June 2007 (2007-06-16), page 507, XP009101917, BRITISH MEDICAL ASSOCIATION, LONDON, GB ISSN: 0003-4967, PERGOLIZZI JOSEPH V ET AL: "Treating Acute Pain in Light of the Chronification of Pain", PAIN MANAGEMENT NURSING, vol. 15, no. 1, 2012, pages 380-390, XP028625563, ISSN: 1524-9042, DOI: 10.1016/J.PMN.2012.07.004, WO-A1-2007/128412, MICHAEL OSSIPOV ET AL: "Descending pain modulation and chronification of pain", CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, vol. 9, no. 1, 1 March 2015 (2015-03-01), pages 143-151, XP55391173,, ANONYMOUS: "Palexia® retard Retardtabletten (Tapentadol)",

FACHINFORMATION ROTE LIST SERVICE, August 2010 (2010-08), pages 1-5, XP002643645, Retrieved from the Internet: URL: <http://www.fachinfo.de/data/fi/jsearch?praep> [retrieved on 2011-06-21], LIANG DEYONG ET AL: "Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision", MOLECULAR PAIN, BIOMED CENTRAL, LONDON, GB, vol. 4, no. 1, 22 February 2008 (2008-02-22), page 7, XP021038581, ISSN: 1744-8069, WO-A2-2009/067703, M. NIESTERS ET AL: "Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy", BRITISH JOURNAL OF ANAESTHESIA., vol. 113, no. 1, 8 April 2014 (2014-04-08), pages 148-156, XP55391174, GB ISSN: 0007-0912, DOI: 10.1093/bja/aeu056, KAI MCGREEVY ET AL: "Preventing chronic pain following acute pain: Risk factors, preventive strategies, and their efficacy", EUROPEAN JOURNAL OF PAIN SUPPLEMENTS, vol. 5, no. 2, 2011, pages 365-376, XP028109432, ISSN: 1754-3207, DOI: 10.1016/J.EUJPS.2011.08.013 [retrieved on 2011-08-10], EP-A1- 1 985 292, JOSEPH PERGOLIZZI ET AL: "The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment", CURRENT MEDICAL RESEARCH AND OPINION, vol. 29, no. 9, 3 July 2013 (2013-07-03), pages 1127-1135, XP55391171, GB ISSN: 0300-7995, DOI: 10.1185/03007995.2013.810615, TZSCHENTKE T M ET AL: "Tapentadol: mit zwei Mechanismen in einem Molekül wirksam gegen nozizeptive und neuropathische Schmerzen. Präklinischer Überblick = Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview", DER SCHMERZ ; ORGAN DER DEUTSCHEN GESELLSCHAFT ZUM STUDIUM DES SCHMERZES, DER ÖSTERREICHISCHEN SCHMERZGESELLSCHAFT UND DER DEUTSCHEN INTERDISZIPLINÄREN VEREINIGUNG FÜR SCHMERZTHERAPIE, SPRINGER, BERLIN, DE, vol. 25, no. 1, 1 February 2011 (2011-02-01), pages 19-25, XP009149538, ISSN: 1432-2129, DOI: 10.1007/S00482-010-1004-1 [retrieved on 2011-01-23], DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2010 (2010-09), WILD JAMES E ET AL: "Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.", Database accession no. NLM20602712 & WILD JAMES E ET AL: "Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.", PAIN PRACTICE : THE OFFICIAL JOURNAL OF WORLD INSTITUTE OF PAIN, vol. 10, no. 5, September 2010 (2010-09), pages 416-427, ISSN: 1533-2500, -: "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCYNTA safely and effectively. See full prescribing information for NUCYNTA", , 1 January 2010 (2010-01-01), XP055482355, Retrieved from the Internet: URL: https://www.accessdata.fda.gov/drugsat_fda_docs/label/2010/022304s003lbl.pdf [retrieved on 2018-06-08], W. A. Macrae: "Chronic post-surgical pain: 10 years on", BRITISH JOURNAL OF ANAESTHESIA., vol. 101, no. 1, 19 April 2008 (2008-04-19), pages 77-86, XP55391050, GB ISSN: 0007-0912, DOI: 10.1093/bja/aen099

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Tapentadol til anvendelse ved forebygging mot kronifisering av smerter.
2. Tapentadol til anvendelse ifølge krav 1, hvori smertene er sentrale eller perifere.
3. Tapentadol til anvendelse ifølge hvilket som helst foregående krav, hvori smertene velges fra gruppen bestående av postoperative smerter, inflammatoriske smerter, smerter i forbindelse med migrene, smerter i forbindelse med hodepine, smerter i forbindelse med irritabel tarmsyndrom, smerter i forbindelse med fibromyalgi artrittsmerter, skjelettsmerter, leddsmarter, gastrointestinale smerter, muskelsmerter, anginasmerter, ansiktssmerter, bekkensmerter, klaudikasjon, postoperative smerter, posttraumatiske smerter, spenningstype hodepine, obstetrikkssmerter, gynekologiske smerter og kjemoterapiinduserte smerter.
4. Tapentadol til anvendelse ifølge hvilket som helst foregående krav, hvori smertene er moderate eller alvorlige.
5. Tapentadol til anvendelse ifølge hvilket som helst foregående krav, hvori tapentadol administreres oralt.
6. Tapentadol til anvendelse ifølge hvilket som helst foregående krav, hvori tapentadol administreres én eller to ganger daglig.
7. Tapentadol til anvendelse ifølge hvilket som helst foregående krav, hvori tapentadol administreres med en daglig dose innenfor området fra 25 til 600 mg.